Wed, Nov 26, 2014, 10:27 AM EST - U.S. Markets close in 5 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Questcor Pharmaceuticals, Inc. (QCOR) Message Board

  • jamiejaytrader jamiejaytrader Dec 8, 2010 12:07 PM Flag

    Huge rise today

    Did i miss some news today? or is there another reason for the sudden huge rise today? anyone?

    Jamie

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • My theory on the run-up is that the newly doubled sales force is selling Acthar with unbridled success. Althougn CEO Baily is tight lipped, the sales force, not being officers of the company and therefore not regulated by SEC regs, are blabbing of their success leading to informed buying by indivuals who now know first hand. Additionally, I'm sure there's doctors who are aware of any success with Acthar and they also have no inhibition of heading to the buy window...Some big blocks have went through, but I would think there's good chance they're from Baily trying to scrape more chips from the pot into his chip rack before the lid gets blown off this thing with he January earnings report. Am I the only one who believes that the NS scripts sold this quarter could be upwards of 30? Last quarter there were only (8) while no effort was even being made to sell them! Oh, and lets not forget there's now 77 sales reps pounding the pavement selling MS scipts like mad and probably blabbing it all over. The writing is on the wall. This slow but steady drift upward with small lots stinks of "little guy" in the know buying..with 93% of the float in the hands of institutions and Mutual funds there's little left to play with. The major players have their chips stacks piled high and there aren't betting into the pot. The short stacks are fighting over the antes and blinds like rabid dogs ie., there are few shares left in play. With the earnings in January,we are going to blow the roof off like the Hiroshima bomb!

    • end of january can't come soon enough! :-)

    • I am pretty confident that the company has been in the market, but it is difficult to say as to how much they have purchased. I know that Don is very much a WALMART type shopper and he is probably acting more like a back stop then getting involoved in a bidding war during a run up like today. I would be disappointed if he did not get us at least 2 million shares before the end of the year.

      The go forward earnings will be adjusted by analysts next year and it will create further upward pressure once the bean counters reset all the ratios. Couple on top of that a CEO that has a bag of cash waiting for the next buying opportunity and you have a recipe for lower dips and higher highs.

      It's all good!

    • A large block went off of around 35k shares to start the climb and a few more followed into what appeared to be some short covering. No public news and in my opinion this is just a good day for the bulls in a longer term bull pattern.

      We are well on our way to reaching 1 billion dollars in market capitalization and we have earnings coming up in Janaury which has the potential of blowing the doors off of the consensus of 18 cents per share.

      We are in a great position entering the new year which should prove to be the most exciting and rewarding year yet for it's shareholders. The diabetes potential has blockbuster ramifications for the long term growth and pps and there is no better place to park your money money in the entire stock universe in my opinion then QCOR.

      QCOR on a one way trip to the Moon!!

      • 1 Reply to mdr0418
      • Here is why the stock is strong. Found it on Etrade and most likely you will find it on QCOR's website.

        Questcor Pharma provides interim results from independent study of H.P. Acthar Gel in patients with advanced diabetic nephropathyFont size: A | A | A6:34 AM ET 11/22/10 | Briefing.com

        Co presents interim results presented from an ongoing, randomized prospective study conducted independently indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function. The new data suggest Acthar may represent a novel pathway for the treatment of proteinuria due to diabetic nephropathy which represents the most common cause of end-stage renal disease in the US

    • Maybe the buyback seems to be underway.Who knows ?

      But one thing is sure: this stock is a bargain below $ 30 if we consider the financial results for Q4 2010 and all the others to come in 2011.

 
QCOR
93.60+1.52(+1.65%)Aug 14 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.